In a groundbreaking presentation at the 15th European Breast Cancer Conference (EBCC15) held in Barcelona, leading researchers provided early and reassuring results from the landmark LORD trial, which investigates the safety and effectiveness of active surveillance as an alternative to immediate surgery for patients diagnosed with low-risk ductal carcinoma in situ (DCIS). This pivotal study challenges long-standing paradigms in breast cancer treatment and opens the door for potentially transformative changes in clinical management.
DCIS represents a condition characterized by the presence of abnormal cells confined within the milk ducts of the breast. While these cells are not invasive carcinoma, there is a risk—albeit low in many cases—that DCIS may progress into invasive breast cancer. Traditionally, DCIS has been aggressively treated with methods such as surgery, radiotherapy, and hormone therapy to preempt such progression. However, mounting evidence suggests that approximately 80% of DCIS cases might never evolve into life-threatening disease, raising critical questions about the necessity and extent of current treatment approaches.
The LORD trial, initiated in 2017 and conducted across nearly 60 hospitals in the Netherlands, specifically addresses whether women with low-grade (grade 1 or 2) DCIS detected via screening could be safely managed with active surveillance rather than undergoing immediate surgical interventions. Professor Jelle Wesseling, a leading pathologist at The Netherlands Cancer Institute and Leiden University Medical Center, emphasized the ethical drive behind the study. He underscored the vital medical principle of “first, do no harm,” advocating for a more balanced treatment strategy that avoids overtreatment without compromising patient safety.
This extensive trial has enrolled 1,423 patients with low-risk DCIS, monitored over an average follow-up period of two years. The initial randomized segment of the study involved 73 participants assigned to either immediate surgery or active surveillance. Subsequent modifications allowed patient preference to guide treatment decisions, resulting in approximately three-quarters opting for close monitoring, thus highlighting a significant patient inclination toward less invasive management when appropriately informed.
Analysis of outcomes revealed that among the 363 patients undergoing initial surgical treatment, pathological examination identified invasive breast cancer in 29 individuals at diagnosis, with an additional four cases emerging during follow-up. In contrast, of the 1,060 patients under active surveillance, 63 were diagnosed with invasive breast cancer over the same period. The trial’s protocol mandated cessation once invasive cancer diagnoses reached 60 in the surveillance group, marking a critical interim endpoint.
Crucially, comparative analysis between the two cohorts demonstrated that invasive tumors detected during active surveillance were marginally larger on average (9 mm) compared to those found at surgery (6 mm) but did not exhibit greater aggressiveness. These findings are particularly significant because they suggest that delayed intervention does not correlate with more dangerous tumor biology, an insight that could reshape risk-benefit considerations inherent to DCIS management.
Professor Wesseling described these preliminary results as reassuring, emphasizing that active surveillance does not equate to neglect of care but rather entails meticulous monitoring with the provision for prompt surgical intervention should the need arise. This nuanced approach could alleviate the psychological and physical burdens associated with potentially unnecessary surgery and adjuvant therapies in many women.
From a broader perspective, the LORD trial contributes essential data to the ongoing debate concerning overdiagnosis and overtreatment in breast cancer care. It highlights the possibility of stratifying patients based on tumor characteristics and individual risk profiles, thereby tailoring management strategies more precisely. Nonetheless, researchers caution that longer-term follow-up remains imperative to fully ascertain the safety and efficacy of surveillance strategies before widespread clinical guideline revisions can be considered.
Patient selection remains a critical focus area, with ongoing research aimed at better understanding which biological and clinical factors predict progression to invasive cancer. Unlocking these predictive markers will enhance personalized medicine approaches, minimizing harm while maximizing benefit. Furthermore, this study prompts a reevaluation of breast cancer screening paradigms, which currently do not distinguish between lesions that require immediate treatment and those amenable to watchful waiting.
The reception of these findings within the clinical community has been cautiously optimistic. Professor Isabel Rubio, Chair of EBCC15 and Head of Breast Surgical Oncology at Clínica Universidad de Navarra in Madrid, endorsed the trial’s contribution to evolving breast cancer management. She acknowledged that the data supports active surveillance as a feasible option for carefully selected patients with low-risk DCIS, which could substantially reduce overtreatment without compromising oncological safety.
As the LORD trial progresses, continued vigilance through meticulous follow-up is essential. The investigators are closely monitoring all participants to track long-term outcomes, aiming to solidify the evidence base for refined, patient-centered DCIS management protocols. Success in this domain would mark a paradigm shift—potentially reducing healthcare costs, preserving quality of life, and ensuring that treatment intensity matches the biological risk.
This research was supported by the KWF Dutch Cancer Society and the Rising Tide Foundation for Clinical Cancer Research, reflecting a commitment to advancing clinical oncology and improving patient outcomes through innovation and evidence-based care.
The early results from the LORD trial represent a significant milestone in breast cancer research, emphasizing a move towards less aggressive and more individualized treatment strategies for DCIS. As understanding deepens, this approach holds promise for transforming the clinical landscape, prioritizing both efficacy and patient well-being.
Subject of Research: People
Article Title: Early Results from the LORD Trial Suggest Active Surveillance as a Safe Alternative to Immediate Surgery for Low-Risk DCIS
News Publication Date: [Not Provided]
Web References: [Not Provided]
References: [Not Provided]
Image Credits: EBCC15 / Jelle Wesseling
Keywords: ductal carcinoma in situ, DCIS, breast cancer, active surveillance, low-risk DCIS, breast cancer treatment, overtreatment, surgery, cancer screening, oncology, cancer research, breast cancer conference
